Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Ogsiveo (nirogacestat)
i
Other names:
PF-03084014 , PF03084014, PF 03084014
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
SpringWorks Therap
Drug class:
γ-secretase inhibitor
Related drugs:
‹
AL101 (1)
Compound E (1)
MRK003 (1)
LY-411575 (0)
MK-0752 (0)
LY3039478 (0)
CPX-POM (0)
AL102 (0)
AL101 (1)
Compound E (1)
MRK003 (1)
LY-411575 (0)
MK-0752 (0)
LY3039478 (0)
CPX-POM (0)
AL102 (0)
›
Associations
(3)
News
Trials
VERI cancer hierarchy
Reset Filters
NOTCH2 mutation
Triple Negative Breast Cancer
NOTCH2 mutation
Triple Negative Breast Cancer
nirogacestat
Sensitive: D – Preclinical
nirogacestat
Sensitive
:
D
nirogacestat
Sensitive: D – Preclinical
nirogacestat
Sensitive
:
D
EGFR T790M
Lung Adenocarcinoma
EGFR T790M
Lung Adenocarcinoma
gefitinib + nirogacestat
Sensitive: D – Preclinical
gefitinib + nirogacestat
Sensitive
:
D
gefitinib + nirogacestat
Sensitive: D – Preclinical
gefitinib + nirogacestat
Sensitive
:
D
NOTCH1 mutation
Triple Negative Breast Cancer
NOTCH1 mutation
Triple Negative Breast Cancer
nirogacestat
Sensitive: D – Preclinical
nirogacestat
Sensitive
:
D
nirogacestat
Sensitive: D – Preclinical
nirogacestat
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login